Jennifer Soung, MD, on Addressing Misconceptions and Managing the Whole Patient in AD

At the Revolutionizing Atopic Dermatitis 2026 conference, Jennifer Soung, MD, board-certified dermatologist and clinical researcher at Southern California Dermatology in Santa Ana and clinical faculty at the University of California, Los Angeles, discussed common misconceptions surrounding atopic dermatitis (AD). In the session with Adam Friedman, MD, FAAD, and E. James Song, MD, FAAD, she focused particularly on the role of food allergies, while emphasizing a comprehensive approach to managing patients with this chronic inflammatory condition.

According to Soung, one of the most frequent questions she receives from patients is whether eliminating certain foods can “cure” their eczema. Food and AD remain areas of significant confusion, with misinformation frequently amplified by social media, online advice, and anecdotal experiences. While food allergies can be associated with AD, she emphasized that dietary elimination is not an appropriate strategy for most patients and should be guided by clinical history rather than broad testing.

“Food and AD is one of those topics that's been so confusing in medicine, filled with so many strong opinions…and sometimes just enough truth to make those myths sound convincing,” she told Dermatology Times.

Soung noted that food allergies are more prevalent among children with AD, affecting approximately 30% of pediatric patients compared with about 11% of adults. However, she cautioned against indiscriminate food allergy panels, explaining that testing should be reserved for patients with symptoms or a clear history of immediate hypersensitivity reactions. Many patients may incorrectly attribute their eczema flares to specific foods, leading to unnecessary dietary restrictions that may negatively affect nutrition and quality of life.

Beyond food allergies, Soung highlighted the importance of evaluating AD as a disease that affects the whole patient. She encourages clinicians to begin consultations by asking patients how their disease impacts them personally, whether through itch, sleep disruption, emotional burden, or limitations on daily activities. Understanding the patient’s priorities can help guide treatment decisions and improve shared decision-making.

She also emphasized the importance of addressing lifestyle factors, including balanced nutrition, consistent sleep, and appropriate skin care routines. Daily bathing, regular moisturization, and sensitive skin care practices remain foundational components of AD management. However, she acknowledged that discussing lifestyle modifications, comorbidities, and treatment options during an initial visit can feel overwhelming for patients and families.

When assessing AD-associated comorbidities, Soung recommended reviewing each patient’s medical history and medications while considering the severity, chronicity, and impact of associated conditions. By addressing both the inflammatory disease and the broader patient experience, dermatology providers can better support individuals living with AD and help separate evidence-based recommendations from common misconceptions.

For more expert insights from RAD 2026, click here.